Stocks · News reference
The Company also announced that it has regained compliance with Nasdaq’s minimum bid price requirement, marking another positive development as Trinity Biotech continues to execute its strategic priorities.Perceptive
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
The contract establishes a framework for Trinovium and RTI to develop and deploy direct-to-chip liquid cooling solutions for artificial intelligence ("AI"), high-performance computing ("HPC") and modular
Trinity Biotech announced continued execution of its transformation strategy, including commercial leadership strengthening in Europe, rollout of upgraded HbA1c column technology, and expansion of its PrePsia™ patent portfolio to nine patents. However, the company received a Nasdaq delisting notice after failing to maintain the $15 million minimum market value of publicly held shares requirement by the August 18, 2026 deadline. The company intends to request a hearing before a Nasdaq panel and is pursuing strategic initiatives to regain compliance.